CAMBRIDGE, Mass., May 6, 2022 – Cellarity, a life sciences company founded by Flagship Pioneering to transform the way medicines are discovered, announced today the first Single Cell and AI in Medicine Symposium to discuss how the intersection of single-cell analysis, AI, and biology is impacting drug discovery and the progress of medical science. This inaugural symposium will take place virtually and in person at Boynton Yards in Sommerville on May 19 from 1pm to 5pm ET.
Impact of Biology and AI on Human Health
Noubar Afeyan, Ph.D.
Founder & CEO of Flagship Pioneering
1:20PM – SESSION 1: Advances in Single-Cell Analysis
Exploring Functional Protein Covariation Across Single Cells
Nikolai Slavov, Ph.D.
Associate Professor of Bioengineering, Allen Distinguished Investigator, and Director of the Single-Cell Proteomics Center at Northeastern University
Integrated Analysis of Single-Cell Data Across Technologies and Modalities
Rahul Satija, Ph.D.
Core Faculty Member at the New York Genome Center and Associate Professor at the Center for Genomics and Systems Biology at New York University
Single-Cell Epigenomics: Gene Regulation at Unprecedented Resolution
Jason Buenrostro, Ph.D.
Associate Member of the Broad Institute and Assistant Professor in the Department of Stem Cell and Regenerative Biology at Harvard University
Round Table: What Does the Future Hold for Single-Cell Analysis?
Moderator: Parul Bordia Doshi
Senior Vice President and Head of Data and Software Engineering at Cellarity
2:30PM – SESSION 2: Uncovering New Disease Biology
Cells in Space: Machine Learning Methods to Unlock the Spatial Interactions of Cells
Barbara Engelhardt, Ph.D.
Senior Investigator at the Gladstone Institutes and Professor at Stanford University
Does Cancer Cell State Matter?
Alex Shalek, Ph.D.
Core Member of the Institute for Medical Engineering and Science, Associate Professor of Chemistry, and Extramural Member of the Koch Institute for Integrative Cancer Research at MIT, Institute Member of the Broad Institute
Lessons Learned from Charting Single-Cell Gut Atlases
José Ordovás-Montañés, Ph.D.
Principal Investigator at Boston Children’s Hospital, Assistant Professor at Harvard Medical School, Associate Member at the Broad Institute, Associate Member at the Ragon Institute, Principal Faculty at Harvard Stem Cell Institute, and Robertson Investigator of the New York Stem Cell Foundation
Single Cell and Spatial Genomics for Next-Generation Neuropathology
Evan Macosko, Ph.D.
Associate Professor of Psychiatry at Harvard Medical School and Institute Member of the Broad Institute
Round Table: How will Uncovering New Biology Impact How We Treat Disease?
Moderator: Sylvia Andrzejewski, Ph.D.
Senior Scientist II at Cellarity
4:00 PM – SESSION 3: AI in Drug Creation
Harnessing Deep Learning for Antibiotic Drug Discovery
Jim Collins, Ph.D.
Termeer Professor of Medical Engineering & Science and Professor of Biological Engineering at MIT, Member of the Harvard-MIT Health Sciences & Technology Faculty, Core Founding Faculty Member of the Wyss Institute for Biologically Inspired Engineering at Harvard University, and an Institute Member of the Broad Institute of MIT and Harvard
AI for Chemical Space Navigation
Connor Coley, Ph.D.
Assistant Professor of Chemical Engineering & Electrical Engineering and Computer Science at MIT
Artificial Intelligence Approaches for Peptide Design
Cesar de la Fuente, Ph.D.
Presidential Assistant Professor at University of Pennsylvania
Round Table: How Is AI Changing the Drug Discovery Paradigm?
Moderator: Jennifer Davoren, Ph.D.
Senior Director and Head of Medicinal Chemistry Design at Cellarity
Cellarity's mission is to fundamentally transform the way medicines are created. Founded by Flagship Pioneering in 2017, Cellarity has developed unique capabilities combining high-resolution data, single cell technologies, and machine learning to encode biology, predict interventions, and purposefully design breakthrough medicines. By focusing on the cellular changes that underlie disease instead of a single target, Cellarity’s approach uncovers new biology and treatments and is applicable to a vast array of disease areas. The company currently has programs underway in metabolic disease, hematology, immuno-oncology, and respiratory disease. The company has raised $123 million as part of a Series B funding round with contributions from funds and accounts managed by Blackrock, The Baupost Group, Banque Pictet on behalf of their clients, and eight other investors alongside Flagship Pioneering.
MEDIA CONTACT: Jessica Yingling, Ph.D., email@example.com